Image de couverture de livre

IL23 Receptor Polymorphism Is a Predictor of Anti‐Tumour Necrosis Factor‐α‐Induced Paradoxical Psoriasis in Inflammatory Bowel Disease

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Navneet Natt, Monica Gindi, Gio R. Dela Cruz, Terry Ponich, James C. Gregor, Nilesh Chande, Melanie D. Beaton, Keith McIntosh, Michael Sey, Reena Khanna, Richard B. Kim, Aze Wilson
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Long‐Term Outcomes Following Withdrawal of Anti‐Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long‐Term Study of GETECCU
par: María José Casanova, et autres
Publié: (2025)

Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL‐17A Inhibitors: A Population‐Based Study
par: Saqr Alsakarneh, et autres
Publié: (2025)

Meta‐Analysis: Improvement of Bowel Urgency With Advanced Therapies for Inflammatory Bowel Disease
par: Purab Patel, et autres
Publié: (2025)

Stability of Classification Systems for Irritable Bowel Syndrome
par: Mais Khasawneh, et autres
Publié: (2025)

Editorial: Allostatic Load and Inflammatory Bowel Disease
par: Jeli Mendoza, et autres
Publié: (2024)

Real‐World Performance of FIT Triage for Symptomatic Colonoscopy: Analysis of the UK National Endoscopy Database ( NED )
par: David Beaton, et autres
Publié: (2026)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease?
par: Matthew D. Coates, et autres
Publié: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease
par: Marco Vincenzo Lenti, et autres
Publié: (2025)

Systematic Review: Stigma Associated With Inflammatory Bowel Disease
par: Suprabhat Giri, et autres
Publié: (2025)

Editorial: Can We Prevent Inflammatory Bowel Disease?
par: Agnes Hiu Yan Ho, et autres
Publié: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
par: Tamar Schildkraut, et autres
Publié: (2024)

Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
par: Uma Mahadevan, et autres
Publié: (2025)

Meta‐Analysis: Prevalence of Eating Disorders in Inflammatory Bowel Disease
par: Quinn Goddard, et autres
Publié: (2025)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
par: Jianhui Zhao, et autres
Publié: (2024)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
par: Fai Fai Ho, et autres
Publié: (2025)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues
par: Stephanie Gold, et autres
Publié: (2025)

Editorial: Rebuilding Rome—Revising Diagnostic Criteria for Irritable Bowel Syndrome
par: Mohsin F. Butt, et autres
Publié: (2024)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
par: Suprabhat Giri, et autres
Publié: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply
par: Bharati Kochar, et autres
Publié: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
par: Virginia Solitano, et autres
Publié: (2024)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease
par: Nicholas Clark, et autres
Publié: (2025)

Letter: Using Anti‐ HBs Titres to Tailor HBV Reactivation Monitoring in Patients With Solid Tumours
par: Tsutomu Nishida, et autres
Publié: (2026)

Meta‐Analysis: Pregnancies With Inflammatory Bowel Disease Complicated by Intrahepatic Cholestasis of Pregnancy
par: Shamim Joudaki, et autres
Publié: (2025)

Overall and Comparative Risk of Shingles With Advanced Therapies in Patients With Inflammatory Bowel Diseases
par: Dhruv Ahuja, et autres
Publié: (2025)

Editorial: Tumour Burden Score and Extrahepatic Progression After TACE —Refining Risk Stratification Beyond the Liver
par: Chien‐Wei Su
Publié: (2026)

Prescribing Inflammatory Bowel Disease Medications in Chronic Kidney Disease: A Practical Guide
par: Lynna Chen, et autres
Publié: (2025)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet?
par: Joyce Wing Yan Mak
Publié: (2025)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply
par: Jessica A. Fitzpatrick, et autres
Publié: (2025)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease. Authors' Reply
par: Cristina Rubín de Célix, et autres
Publié: (2025)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease
par: Cong Dai, et autres
Publié: (2024)

Editorial: Shooting in the Dark—The Problem With Empiric Antispasmodics for Abdominal Pain in Inflammatory Bowel Disease
par: Jane Lim, et autres
Publié: (2025)

Letter: Tumour Burden Score for Predicting Extrahepatic Metastasis in Hepatocellular Carcinoma After Curative Resection. Authors' Reply
par: Elisa Pinto, et autres
Publié: (2026)

Letter: Are All Extra‐Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story?
par: Liang Jiao, et autres
Publié: (2026)

Research Communication: An Observational Cohort Study on Risk of Ovarian Cancer in Women with Irritable Bowel Syndrome
par: Andrea Shin, et autres
Publié: (2025)

Prevalence and Predictors of Symptoms of Anxiety or Depression at Diagnosis in Patients With Inflammatory Bowel Disease: An Inception Cohort
par: Christy Riggott, et autres
Publié: (2025)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients With Inflammatory Bowel Disease
par: Chang Liu, et autres
Publié: (2026)

Persistence of Symptoms of Anxiety and Depression in Inflammatory Bowel Disease: A Longitudinal Follow‐Up Study
par: Christy Riggott, et autres
Publié: (2025)

Maternal and Perinatal Outcomes in Pregnant Women With Comorbid Inflammatory Bowel Disease and Chronic Liver Disease
par: Jessica D. Lee, et autres
Publié: (2025)

Validating Simple Modifications to the Rome IV Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care
par: Vivek C. Goodoory, et autres
Publié: (2024)

Editorial: Is There a Role for Therapeutic Drug Monitoring of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease?
par: Konstantinos Papamichael, et autres
Publié: (2024)